bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.…
BIAF Stock Dips Post Q3 Earnings Despite Rising Test Demand, Sales Down
bioAffinity Technologies (NASDAQ: BIAF) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 57 employees.
The shares were at 1.650 USD on 20 November 2026, down 94.7% over 52 weeks. Its 52-week range is 1.630 USD to 80.70 USD: the price is 98.0% below the high and 1.2% above the low.
Its market capitalisation is 3.00M USD.
bioAffinity Technologies reports return on equity of -204.9%, an operating margin of -246.1% and revenue down 26.0% year over year.
It holds more cash than debt, a net cash position of 1.05M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.